scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1001707106 |
P356 | DOI | 10.1038/NATURE02214 |
P3181 | OpenCitations bibliographic resource ID | 2597600 |
P698 | PubMed publication ID | 14765194 |
P5875 | ResearchGate publication ID | 8884660 |
P50 | author | Edward Tuddenham | Q5345654 |
P2093 | author name string | Tim M Strom | |
Johannes Oldenburg | |||
Erhard Seifried | |||
Vytautas Ivaskevicius | |||
Inge Scharrer | |||
Clemens R Müller | |||
Konstanze Hörtnagel | |||
Hans-Joachim Pelz | |||
Simone Rost | |||
Andreas Fregin | |||
Ernst Conzelmann | |||
Knut Lappegard | |||
P2860 | cites work | Vitamin K Dependent Modifications of Glutamic Acid Residues in Prothrombin | Q24620022 |
The vitamin K-dependent carboxylase | Q28207074 | ||
Metabolism of vitamin K and vitamin K 2,3-epoxide via interaction with a common disulfide | Q28272704 | ||
Characterization and purification of the vitamin K1 2,3 epoxide reductases system from rat liver | Q28568888 | ||
An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria | Q29998977 | ||
Identification of a Drosophila vitamin K-dependent gamma-glutamyl carboxylase | Q33180094 | ||
gamma -Glutamyl carboxylation: An extracellular posttranslational modification that antedates the divergence of molluscs, arthropods, and chordates | Q34008887 | ||
Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin | Q34564856 | ||
A major gene controlling warfarin-resistance in the house mouse | Q36250369 | ||
Genomic assignment of the warfarin resistance locus, Rw, in the rat. | Q41675552 | ||
A molecular mechanism for genetic warfarin resistance in the rat. | Q43771296 | ||
Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. | Q44182924 | ||
Cloning of rat vitamin K-dependent gamma-glutamyl carboxylase and developmentally regulated gene expression in postimplantation embryos | Q48021715 | ||
Warfarin-Resistance Genotype Determination in the Norway Rat, Rattus Norvegicus | Q54569097 | ||
Heritable Resistance to Warfarin in Rats | Q54699767 | ||
Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomes | Q71138461 | ||
Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane | Q73853938 | ||
P433 | issue | 6974 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | (RS)-warfarin | Q407431 |
coagulation factor deficiency | Q18971506 | ||
Vitamin K epoxide reductase complex, subunit 1 | Q21980287 | ||
Warfarin resistance | Q24975519 | ||
P304 | page(s) | 537-41 | |
P577 | publication date | 2004-02-05 | |
P1433 | published in | Nature | Q180445 |
P1476 | title | Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 | |
P478 | volume | 427 |
Q33517162 | 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal |
Q79218172 | 1173C>T polymorphism in VKORC1 modulates the required warfarin dose |
Q24817078 | A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk |
Q53689662 | A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX. |
Q39953190 | A PCR method for VKORC1 G-1639A and CYP2C9 A1075C genotyping useful to warfarin therapy among Japanese |
Q50775104 | A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. |
Q37088955 | A cardiovascular phenotype in warfarin-resistant Vkorc1 mutant rats |
Q30568150 | A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites |
Q36835176 | A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose |
Q46144961 | A genotyping method for VKORC1 1173C > T by Pyrosequencing technology. |
Q35025482 | A hetero-dimer model for concerted action of vitamin K carboxylase and vitamin K reductase in vitamin K cycle. |
Q46872515 | A mass spectrometry-based proteomic analysis of Homer2-interacting proteins in the mouse brain |
Q46639196 | A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon |
Q42434975 | A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay |
Q37700486 | A new nested allele-specific multiplex polymerase chain reaction method for haplotyping of VKORC1 gene to predict warfarin sensitivity |
Q34418092 | A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. |
Q34085379 | A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans |
Q58379508 | A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy |
Q46760496 | A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfarin resistance |
Q46566220 | A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance |
Q46466680 | Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort |
Q46747889 | Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects. |
Q33575234 | Adaptative evolution of the Vkorc1 gene in Mus musculus domesticus is influenced by the selective pressure of anticoagulant rodenticides. |
Q35154050 | Adaptive introgression of anticoagulant rodent poison resistance by hybridization between old world mice |
Q92509688 | Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects |
Q46885444 | Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. |
Q33585844 | Analysis of vkorc1 polymorphisms in Norway rats using the roof rat as outgroup |
Q90663188 | Antagonists of Vitamin K-Popular Coumarin Drugs and New Synthetic and Natural Coumarin Derivatives |
Q89233044 | Anticoagulants: What is new and what is the standard? |
Q33846255 | Applied pharmacogenomics in cardiovascular medicine |
Q36624112 | Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen |
Q57768645 | Are water vole resistant to anticoagulant rodenticides following field treatments? |
Q48901873 | Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization. |
Q87307841 | Association between VKORC1 gene polymorphisms and ischemic cerebrovascular disease in Chinese Han population |
Q39950111 | Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals |
Q46908254 | Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients |
Q47141762 | Association of Warfarin Therapy with APOE and VKORC1 Genes Polymorphism in Iranian Population |
Q35082782 | Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis |
Q35681000 | Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans |
Q35633802 | Association of warfarin dose with genes involved in its action and metabolism |
Q81154646 | Automated analysis of conserved syntenies for the zebrafish genome |
Q36954475 | Bacterial species exhibit diversity in their mechanisms and capacity for protein disulfide bond formation. |
Q49612005 | Benefit of pre-emptive pharmacogenetic information on clinical outcome. |
Q40287387 | Biochemical characterization of Drosophila gamma-glutamyl carboxylase and its role in fly development |
Q38858766 | Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method |
Q35051893 | Bioinformatics challenges for personalized medicine |
Q33990359 | CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies |
Q46936372 | CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients |
Q42738272 | Can we more efficiently save patients with vitamin K-dependent coagulopathy caused by superwarfarin intoxication? |
Q35025518 | Cardiovascular pharmacogenomics and individualized drug therapy |
Q26801183 | Cardiovascular pharmacogenomics: current status and future directions |
Q36487290 | Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics? |
Q33376860 | Case studies in anticoagulation management |
Q21563496 | Chapter 7: Pharmacogenomics |
Q93162370 | Clinical Model for Predicting Warfarin Sensitivity |
Q42335970 | Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines |
Q38961083 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update |
Q27008360 | Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing |
Q37606335 | Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement |
Q36741112 | Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients |
Q26849254 | Clinical application of cardiovascular pharmacogenetics |
Q34179616 | Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin |
Q26823542 | Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? |
Q37071882 | Co-existent pseudoxanthoma elasticum and vitamin K-dependent coagulation factor deficiency: compound heterozygosity for mutations in the GGCX gene |
Q46950581 | Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans |
Q36303810 | Combinatorial pharmacogenetics |
Q34417386 | Common VKORC1 and GGCX polymorphisms associated with warfarin dose |
Q37115953 | Comparative genomics for detecting human disease genes |
Q98178716 | Comparison of two reducing agents dithiothreitol and tris(3-hydroxypropyl)phosphine for in vitro kinetic assay of vitamin K epoxide reductase |
Q46133587 | Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort |
Q35849078 | Compound heterozygosity of novel missense mutations in the gamma-glutamyl-carboxylase gene causes hereditary combined vitamin K-dependent coagulation factor deficiency |
Q41962781 | Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling |
Q43182272 | Consequences of morphology on molecularly imprinted polymer-ligand recognition. |
Q35008925 | Consequences of the Y139F Vkorc1 mutation on resistance to AVKs: in-vivo investigation in a 7th generation of congenic Y139F strain of rats |
Q24337424 | Conserved loop cysteines of vitamin K epoxide reductase complex subunit 1-like 1 (VKORC1L1) are involved in its active site regeneration |
Q36545011 | Contribution of CYP2C9 to variability in vitamin K antagonist metabolism |
Q46979156 | Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients |
Q34522122 | Coumatetralyl resistance of Rattus tanezumi infesting oil palm plantations in Indonesia |
Q56512655 | Cryptic genetic diversity in Rattus of the San Francisco Bay region, California |
Q37960511 | Current challenges in personalizing warfarin therapy |
Q37990337 | Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use. |
Q41984591 | Detecting species-site dependencies in large multiple sequence alignments |
Q54050000 | Detection of the anticoagulant drug warfarin by palladium complexes. |
Q36511894 | Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients |
Q51750909 | Development of an Ecofriendly Anticoagulant Rodenticide Based on the Stereochemistry of Difenacoum. |
Q47688705 | Development of neuro-fuzzy model to explore gene-nutrient interactions modulating warfarin dose requirement |
Q37310023 | Dissecting the Effect of Genetic Variation on the Hepatic Expression of Drug Disposition Genes across the Collaborative Cross Mouse Strains |
Q34548788 | Distribution of anticoagulant rodenticide resistance in Rattus norvegicus in the Netherlands according to Vkorc1 mutations |
Q40056159 | Distribution of rodenticide resistance and zoonotic pathogens in Norway rats in Lower Saxony and Hamburg, Germany |
Q33723782 | Disulfide bond formation in prokaryotes: history, diversity and design |
Q40204873 | Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum. A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reduction |
Q44486357 | Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations |
Q42707554 | Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients |
Q46927387 | Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm |
Q48905886 | Effect of gene polymorphims on the warfarin treatment at initial stage. |
Q28276514 | Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin |
Q45882501 | Effective hemostasis during minor surgery in a case of hereditary combined deficiency of vitamin K-dependent clotting factors |
Q45880221 | Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy |
Q64237015 | Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy |
Q28566882 | Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system |
Q58590457 | Ensemble of machine learning algorithms using the stacked generalization approach to estimate the warfarin dose |
Q37486720 | Epilepsy pharmacogenetics |
Q93102917 | Establishment of the Variation of Vitamin K Status According to Vkorc1 Point Mutations Using Rat Models |
Q33410725 | Estimation of the warfarin dose with clinical and pharmacogenetic data |
Q46778368 | Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients |
Q35758421 | Evaluation of genetic factors for warfarin dose prediction |
Q33912911 | Evaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum |
Q37100171 | Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells |
Q37256499 | Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice |
Q46747731 | Evidence of a target resistance to antivitamin K rodenticides in the roof rat Rattus rattus: identification and characterisation of a novel Y25F mutation in the Vkorc1 gene. |
Q53966193 | Exacerbation of hereditary warfarin resistance by azathioprine. |
Q38098452 | Expanding role of pharmacogenomics in the management of cardiovascular disorders |
Q34994877 | Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. |
Q38607382 | Extracellular Thiol Isomerases and Their Role in Thrombus Formation |
Q37098826 | Familial deficiency of vitamin K-dependent clotting factors |
Q35839891 | Fatal hemorrhage in mice lacking gamma-glutamyl carboxylase |
Q35894964 | Food Reformulation, Responsive Regulation, and "Regulatory Scaffolding": Strengthening Performance of Salt Reduction Programs in Australia and the United Kingdom |
Q39159490 | Frequency of Common VKORC1 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population. |
Q37806982 | From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics |
Q83509385 | From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics |
Q36691790 | From molecular diagnostics to personalized testing |
Q39074534 | Functional Study of the Vitamin K Cycle Enzymes in Live Cells |
Q34707195 | Functional study of the vitamin K cycle in mammalian cells |
Q37293364 | G-1639A but Not C1173T VKORC1 Gene Polymorphism Is Related to Ischemic Stroke and Its Various Risk Factors in Ukrainian Population. |
Q35184466 | GGCX and VKORC1 inhibit osteocalcin endocrine functions. |
Q39104527 | GGCX-Associated Phenotypes: An Overview in Search of Genotype-Phenotype Correlations |
Q34569916 | Genes encoding vitamin-K epoxide reductase are present in Drosophila and trypanosomatid protists |
Q90077761 | Genetic Basis of Adaptation and Maladaptation via Balancing Selection |
Q36354529 | Genetic Polymorphisms Analysis of Pharmacogenomic VIP Variants in Miao Ethnic Group of Southwest China. |
Q43216291 | Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. |
Q83343848 | Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population |
Q37777419 | Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk |
Q35669037 | Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China |
Q34538709 | Genetic variants of the vitamin K dependent coagulation system and intraventricular hemorrhage in preterm infants |
Q36813817 | Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population. |
Q37126654 | Genetic variations and their influence on risk and treatment of venous thrombosis |
Q30418104 | Genetics and cardiovascular disease: a policy statement from the American Heart Association. |
Q33352008 | Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel |
Q37998525 | Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments |
Q34934523 | Genetics of warfarin sensitivity in an emergency department population with thromboembolic. |
Q90714284 | Genome-wide analyses disclose the distinctive HLA architecture and the pharmacogenetic landscape of the Somali population |
Q49931634 | Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records. |
Q38292930 | Genomic architecture of pharmacological efficacy and adverse events |
Q38114005 | Genomic medicine: a decade of successes, challenges, and opportunities |
Q35252277 | Genomics and drug response |
Q38206853 | Genomics of bleeding disorders. |
Q36393911 | Genotype-based clinical trials in cardiovascular disease |
Q38321269 | Genotype-guided coumarin dosing: where are we now and where do we need to go next? |
Q46906726 | Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin |
Q66679197 | Harnessing host-virus evolution in antiviral therapy and immunotherapy |
Q34035983 | Hereditary combined deficiency of the vitamin K-dependent clotting factors |
Q33802999 | High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9. |
Q51906653 | High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population. |
Q92158487 | House Mice as a Real Sanitary Threat of Human and Animal Leptospirosis: Proposal for Integrated Management |
Q35915743 | How to evaluate phenotype-genotype relationship in rare coagulation haemorrhagic disorders: examples from FVII deficiency |
Q35689626 | Human herpesvirus 8 viral interleukin-6 interacts with splice variant 2 of vitamin K epoxide reductase complex subunit 1. |
Q24294610 | Human vitamin K 2,3-epoxide reductase complex subunit 1-like 1 (VKORC1L1) mediates vitamin K-dependent intracellular antioxidant function |
Q36298281 | Human vitamin K epoxide reductase and its bacterial homologue have different membrane topologies and reaction mechanisms |
Q37264550 | Identifying genetic components of drug response in mice |
Q35037456 | Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing |
Q36599219 | Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians. |
Q26787099 | Impact of New Genomic Technologies on Understanding Adverse Drug Reactions |
Q64111486 | Impact of gene polymorphism on the initiation and maintenance phases of warfarin therapy in Chinese patients undergoing heart valve replacement |
Q39537454 | Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. |
Q33990428 | Implementing genotype-guided antithrombotic therapy |
Q37328481 | Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. |
Q40395774 | Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle |
Q38534584 | Industrial production of clotting factors: Challenges of expression, and choice of host cells |
Q37334140 | Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis |
Q40132047 | Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array |
Q53702260 | Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population. |
Q58955464 | Influence of proton pump inhibitors andVKORC1mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study |
Q46970476 | Inherited warfarin resistance in Indian patients: does it occur? |
Q33591624 | Inhibition of bacterial disulfide bond formation by the anticoagulant warfarin |
Q35427581 | Insights into mammalian biology from the wild house mouse Mus musculus |
Q47982335 | Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans |
Q37345384 | Inter and intra ethnic variation of vitamin K epoxide reductase complex and cytochrome P450 4F2 genetic polymorphisms and their prevalence in South Indian population |
Q47610685 | Intramembrane Thiol Oxidoreductases: Evolutionary Convergence and Structural Controversy. |
Q42872449 | Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran |
Q36361911 | Large-scale structure of brown rat (Rattus norvegicus) populations in England: effects on rodenticide resistance. |
Q95318678 | Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities |
Q28074008 | Mapping genetic research in non-communicable disease publications in selected Arab countries: first step towards a guided research agenda |
Q28601618 | Mapping the genomic architecture of adaptive traits with interspecific introgressive origin: a coalescent-based approach |
Q37724253 | Mechanisms of oxidative protein folding in the bacterial cell envelope |
Q90114649 | Mediation of the Acute Stress Response by the Skeleton |
Q53904076 | Medicine: K is for koagulation. |
Q36850120 | Membrane Cholesterol Modulates Superwarfarin Toxicity |
Q47344221 | Membrane Protein Structure in Live Cells: Methodology for Studying Drug Interaction by Mass Spectrometry-Based Footprinting. |
Q34700221 | Membrane topology and mutational analysis of Mycobacterium tuberculosis VKOR, a protein involved in disulfide bond formation and a homologue of human vitamin K epoxide reductase |
Q52655392 | Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation. |
Q58743826 | Missense mutation of VKORC1 leads to medial arterial calcification in rats |
Q28658402 | Mitochondrial DNA phylogeography of the Norway rat |
Q49430019 | Molecular Genetic Diagnosis of the Inherited Bleeding Disorders: Are We Close to the Perfect Test? |
Q52428235 | Molecular basis of the first reported clinical case of congenital combined deficiency of coagulation factors. |
Q39736279 | Monitoring the distribution of warfarin in blood plasma |
Q37613680 | Multiple gene interaction and modulation of hemostatic balance |
Q79840055 | Multiple gene polymorphisms and warfarin sensitivity |
Q98878656 | Multiplexed measurement of variant abundance and activity reveals VKOR topology, active site and human variant impact |
Q33979143 | Mutations in the GGCX and ABCC6 genes in a family with pseudoxanthoma elasticum-like phenotypes |
Q35635177 | Mycobacterium tuberculosis vitamin K epoxide reductase homologue supports vitamin K-dependent carboxylation in mammalian cells |
Q41390942 | NPC1L1 is a key regulator of intestinal vitamin K absorption and a modulator of warfarin therapy |
Q37119663 | National and international registries of rare bleeding disorders |
Q41261871 | New insights into the catalytic mechanism of vitamin K epoxide reductase (VKORC1) - The catalytic properties of the major mutations of rVKORC1 explain the biological cost associated to mutations. |
Q33364524 | New pieces to an old puzzle: identifying the warfarin-binding site that prevents clotting |
Q33888697 | Nothing in evolution makes sense except in the light of DNA. |
Q42733103 | Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population |
Q38238560 | Novel droplet platforms for the detection of disease biomarkers |
Q24304387 | Novel insight into the mechanism of the vitamin K oxidoreductase (VKOR): electron relay through Cys43 and Cys51 reduces VKOR to allow vitamin K reduction and facilitation of vitamin K-dependent protein carboxylation |
Q33406630 | Novel mutations in the VKORC1 gene of wild rats and mice--a response to 50 years of selection pressure by warfarin? |
Q38796447 | Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose |
Q47823825 | Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake. |
Q88487480 | Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation |
Q38078754 | Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms |
Q34252907 | Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
Q35763328 | Overview of the development of personalized genomic medicine and surgery |
Q33602704 | Paving the Way to Personalized Genomic Medicine: Steps to Successful Implementation |
Q38749764 | Personalised dosing of medicines for children |
Q36380430 | Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects? |
Q36965849 | Personalized medicine in thrombosis: back to the future |
Q42647888 | PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics |
Q38782191 | Pharmacogenetic Implementation Lessons From the "Real World". |
Q38266460 | Pharmacogenetic aspects of coumarinic oral anticoagulant therapies |
Q38214388 | Pharmacogenetic biomarkers for predicting drug response. |
Q45945749 | Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate. |
Q37768070 | Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. |
Q37087348 | Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin |
Q37151528 | Pharmacogenetic testing: Current Evidence of Clinical Utility |
Q27006860 | Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon |
Q26859221 | Pharmacogenetics and anaesthesia: the value of genetic profiling |
Q36974672 | Pharmacogenetics and cardiovascular disease--implications for personalized medicine |
Q37772183 | Pharmacogenetics and human genetic polymorphisms |
Q39469904 | Pharmacogenetics aspects of oral anticoagulants therapy |
Q34458720 | Pharmacogenetics in Jewish populations. |
Q38094070 | Pharmacogenetics in cardiovascular disorders: an update on the principal drugs. |
Q37275470 | Pharmacogenetics in drug discovery and development: a translational perspective |
Q35038052 | Pharmacogenetics in drug regulation: promise, potential and pitfalls |
Q57302675 | Pharmacogenetics of Adverse Drug Reactions |
Q34219746 | Pharmacogenetics of anticoagulants. |
Q36543128 | Pharmacogenetics of chronic cardiovascular drugs: applications and implications |
Q43115875 | Pharmacogenetics of coumarinic oral anticoagulants |
Q37766148 | Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics |
Q35762123 | Pharmacogenetics of metformin response: a step in the path toward personalized medicine |
Q37242614 | Pharmacogenetics of oral anticoagulants: a basis for dose individualization |
Q36656419 | Pharmacogenetics of target genes across the warfarin pharmacological pathway |
Q37461474 | Pharmacogenetics of vitamin K antagonists: useful or hype? |
Q33819050 | Pharmacogenetics of warfarin: challenges and opportunities |
Q36597343 | Pharmacogenetics of warfarin: current status and future challenges |
Q46406579 | Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients |
Q36956360 | Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues |
Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
Q47776901 | Pharmacogenetics: a general review on progress to date |
Q31144283 | Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment |
Q34171192 | Pharmacogenetics: from bench to byte--an update of guidelines |
Q34965532 | Pharmacogenetics: from discovery to patient care |
Q47357309 | Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments |
Q37378994 | Pharmacogenomic progress in individualized dosing of key drugs for cancer patients |
Q92506521 | Pharmacogenomics |
Q57179825 | Pharmacogenomics Aspect of Warfarin Therapy |
Q48125765 | Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen |
Q38607878 | Pharmacogenomics and Implications for Nursing Practice |
Q26997380 | Pharmacogenomics and cardiovascular disease |
Q28083875 | Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population |
Q36326202 | Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy |
Q37434634 | Pharmacogenomics of anticoagulants: steps toward personal dosage |
Q37367170 | Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery |
Q33891714 | Pharmacogenomics: Current State-of-the-Art |
Q34137575 | Pharmacogenomics: a systems approach |
Q36658763 | Pharmacogenomics: challenges and opportunities |
Q34976915 | Pharmacogenomics: the genetics of variable drug responses |
Q43176747 | Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs |
Q37212206 | Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians |
Q40673326 | Phylogeny of the Vitamin K 2,3-Epoxide Reductase (VKOR) Family and Evolutionary Relationship to the Disulfide Bond Formation Protein B (DsbB) Family |
Q40681407 | Polymorphism in vkorc1 Gene of Natal Multimammate Mice, Mastomys natalensis, in Tanzania |
Q36930160 | Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation |
Q79451353 | Polymorphisms in vitamin K-dependent gamma-carboxylation-related genes influence interindividual variability in plasma protein C and protein S activities in the general population |
Q37742075 | Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population |
Q36087965 | Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes |
Q34534993 | Positive selection in the chromosome 16 VKORC1 genomic region has contributed to the variability of anticoagulant response in humans |
Q39224845 | Precision Cardiovascular Medicine: State of Genetic Testing. |
Q91468339 | Precision dosing of warfarin: open questions and strategies |
Q35991881 | Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record |
Q36044022 | Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes |
Q37989489 | Prediction of warfarin dose: why, when and how? |
Q54320441 | Predictive value of the vitamin K epoxide reductase complex subunit 1 G-1639A and C1173T single nucleotide polymorphisms in retinal vein occlusion. |
Q33990441 | Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. |
Q50027474 | Problems in anticoagulation of a patient with antibiotic treatment for endocarditis: interaction of rifampicin and vitamin K antagonists. |
Q36555934 | Process map proposal for the validation of genomic biomarkers |
Q35221146 | Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2 |
Q35189822 | Quantum Chemical Study of the Mechanism of Action of Vitamin K Carboxylase in Solvent |
Q98188932 | Rat models of human diseases and related phenotypes: a systematic inventory of the causative genes |
Q47757110 | Recent natural selection causes adaptive evolution of an avian polygenic trait. |
Q37603199 | Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis |
Q36835168 | Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement |
Q90149496 | Resistance to anticoagulant rodenticides in Martinique could lead to inefficient rodent control in a context of endemic leptospirosis |
Q26827835 | Reversal of oral anticoagulation |
Q56784668 | Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow-up study |
Q36848449 | Role of pharmacogenomics in the management of traditional and novel oral anticoagulants |
Q34324148 | Selective sweep mapping of genes with large phenotypic effects |
Q37741368 | Serum pharmacokinetics and coagulation aberration induced by sodium dehydroacetate in male and female Wistar rats |
Q46316268 | Shifting paradigms in the pharmacogenetics of warfarin |
Q50693478 | Simulating sequential multiple assignment randomized trials to generate optimal personalized warfarin dosing strategies. |
Q28081943 | Some Important Milestones in the Field of Blood Clotting |
Q52582864 | Stabilization of warfarin-binding pocket of VKORC1 and VKORL1 by a peripheral region determines their different sensitivity to warfarin inhibition. |
Q61810345 | Structural Insights into Phylloquinone (Vitamin K1), Menaquinone (MK4, MK7), and Menadione (Vitamin K3) Binding to VKORC1 |
Q26796613 | Structural Modeling Insights into Human VKORC1 Phenotypes |
Q28086880 | Structural and functional insights into enzymes of the vitamin K cycle |
Q38103055 | Structural and functional insights into human vitamin K epoxide reductase and vitamin K epoxide reductase-like1. |
Q37122098 | Structure and function of vitamin K epoxide reductase |
Q27659264 | Structure of a bacterial homologue of vitamin K epoxide reductase |
Q53785252 | Study of the efficiency of anticoagulant rodenticides to control Mus musculus domesticus introgressed with Mus spretus Vkorc1. |
Q79701040 | Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity |
Q26824166 | Systems pharmacology: network analysis to identify multiscale mechanisms of drug action |
Q35819380 | TAM receptor signaling in immune homeostasis |
Q51489676 | The Creating an Optimal Warfarin Nomogram (CROWN) Study. |
Q92087148 | The Effect of Demographic Factors and VKORC1 1639 G>A Genotypes on Estimated Warfarin Maintenance Dose in Iranian Patients Under Warfarin Therapy |
Q46573199 | The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations. |
Q28306899 | The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients |
Q37646912 | The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm |
Q90950831 | The effect of genetic and nongenetic factors on warfarin dose variability in Qatari population |
Q97568966 | The effect of the VKORC1 promoter variant on warfarin responsiveness in the Saudi WArfarin Pharmacogenetic (SWAP) cohort |
Q37083446 | The emerging threat of superwarfarins: history, detection, mechanisms, and countermeasures. |
Q36294461 | The future of warfarin pharmacogenetics in under-represented minority groups |
Q34530230 | The future prospects of pharmacogenetics in oral anticoagulation therapy |
Q28589135 | The genetic basis of resistance to anticoagulants in rodents |
Q53233863 | The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. |
Q80098649 | The genetics of vitamin K antagonists |
Q43117858 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population |
Q38151546 | The impact of germline mutations on targeted therapy |
Q28576911 | The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats |
Q37071087 | The largest prospective warfarin-treated cohort supports genetic forecasting |
Q36192806 | The pharmacogenetics of coumarin therapy. |
Q34378782 | The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. |
Q92982737 | The potential of VKORC1 polymorphisms in Mustelidae for evolving anticoagulant resistance through selection along the food chain |
Q53800446 | The potential of coumatetralyl enhanced by cholecalciferol in the control of anticoagulant-resistant Norway rats (Rattus norvegicus). |
Q35882779 | The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation |
Q36446904 | The risks of warfarin use in the elderly. |
Q28274345 | The vitamin K cycle |
Q34443182 | The vitamin K cycle. |
Q28115117 | The vitamin K oxidoreductase is a multimer that efficiently reduces vitamin K epoxide to hydroquinone to allow vitamin K-dependent protein carboxylation |
Q42664012 | The vitamin K-dependent carboxylase has been acquired by Leptospira pathogens and shows altered activity that suggests a role other than protein carboxylation |
Q43299004 | Therapeutic efficacy of acenocoumarol in a warfarin-resistant patient with deep venous thrombosis: a case report |
Q44460442 | Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment |
Q35977663 | Treatment of venous thromboembolism and long-term prevention of recurrence: present treatment options and ximelagatran |
Q87608479 | Turn-on type chemical sensing of vitamin K4 by fluorene dendrimers with naphthalene segments |
Q37322151 | Understanding the pharmacogenetic approach to warfarin dosing |
Q39343194 | Uniparental disomy causes deficiencies of vitamin K-dependent proteins |
Q33922958 | Unraveling human complexity and disease with systems biology and personalized medicine |
Q37074097 | Use of genetic and nongenetic factors in warfarin dosing algorithms |
Q50101823 | VKOR paralog VKORC1L1 supports vitamin K-dependent protein carboxylation in vivo. |
Q51359784 | VKOR variant and sex are the main influencing factors on bromadiolone tolerance of the house mouse (Mus musculus L.). |
Q43106358 | VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement |
Q42112505 | VKORC1 ER mislocalization causes rare disease |
Q63865844 | VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement |
Q46238853 | VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients |
Q46548969 | VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. |
Q37552063 | VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients |
Q64046002 | VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites |
Q26799185 | VKORC1 and VKORC1L1: Why do Vertebrates Have Two Vitamin K 2,3-Epoxide Reductases? |
Q28274335 | VKORC1 and the vitamin K cycle |
Q33778446 | VKORC1 common variation and bone mineral density in the Third National Health and Nutrition Examination Survey |
Q28476502 | VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarker |
Q41968877 | VKORC1 pharmacogenomics summary |
Q42879834 | VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications |
Q50294868 | VKORC1 reduces vitamin K epoxide to MK4 (vitamin K hydroquinone) |
Q84854719 | VKORC1 rs2359612C allele is associated with increased risk of coronary artery disease in the presence of coronary calcification |
Q53079086 | VKORC1 sequence variants associated with resistance to anticoagulant rodenticides in Irish populations of Rattus norvegicus and Mus musculus domesticus. |
Q37213180 | VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study |
Q47345423 | VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study. |
Q42907084 | VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China |
Q36609814 | VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation |
Q37122109 | VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors |
Q90523212 | VKORC1L1, An Enzyme Mediating the Effect of Vitamin K in Liver and Extrahepatic Tissues |
Q28114887 | VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy |
Q33813830 | Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing |
Q38983845 | Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients. |
Q45004041 | Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics |
Q37164469 | Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. |
Q47249966 | Vitamin K and cancer |
Q26783713 | Vitamin K and hepatocellular carcinoma: The basic and clinic |
Q42973992 | Vitamin K epoxide reductase (VKORC1) gene mutations in osteoporosis: A pilot study |
Q47287209 | Vitamin K epoxide reductase and its paralogous enzyme have different structures and functions |
Q45749835 | Vitamin K epoxide reductase complex 1 (VKORC1) haplotypes in healthy Hungarian and Roma population samples. |
Q33388562 | Vitamin K epoxide reductase complex subunit 1 (Vkorc1) haplotype diversity in mouse priority strains |
Q34093937 | Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners |
Q51413598 | Vitamin K requirement and reproduction in bromadiolone-resistant Norway rats. |
Q24295256 | Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts |
Q28274354 | Vitamin K-dependent carboxylation |
Q28274366 | Vitamin K-dependent gamma-glutamylcarboxylation: an ancient posttranslational modification |
Q35127469 | Vitamin K-dependent proteins in Ciona intestinalis, a basal chordate lacking a blood coagulation cascade |
Q46557622 | Vkorc1 sequencing suggests anticoagulant resistance in rats in New Zealand |
Q42701736 | Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors |
Q28468726 | Warfarin Pharmacogenetics: New Life for an Old Drug |
Q51733284 | Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase. |
Q51273552 | Warfarin and vitamin K compete for binding to Phe55 in human VKOR. |
Q46542560 | Warfarin dose related to apolipoprotein E (APOE) genotype |
Q81887452 | Warfarin pharmacogenetics |
Q34746605 | Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. |
Q28395337 | Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups |
Q27027304 | Warfarin pharmacogenetics: does more accurate dosing benefit patients? |
Q37122112 | Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin |
Q41168727 | Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer. |
Q55425566 | Warfarin, a juggler's demise. |
Q43012628 | Warfarin: a case history in pharmacogenetics |
Q38043222 | What is the evidence for heterozygote advantage selection? |
Q38300335 | Zebrafish vitamin K epoxide reductases: expression in vivo, along extracellular matrix mineralization and under phylloquinone and warfarin in vitro exposure. |
Q82812011 | [Intracerebral hemorrhage related to anticoagulant therapy] |
Q84007375 | [New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring] |
Q86843930 | [Pharmacogenetics. Clinical relevance in anesthsiology] |
Q57283244 | mTOR and ERK regulate VKORC1 expression in both hepatoma cells and hepatocytes which influence blood coagulation |
Q40288458 | r-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step. |
Q35848852 | siRNA silencing of calumenin enhances functional factor IX production |
Q64106272 | variants as significant predictors of warfarin dose in Emiratis |
Search more.